The DMD Knockout K-562 Polyclonal Cells offered by Ascent Research are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the DMD gene in the human K-562 chronic myelogenous leukemia line. This heterogeneous pool contains diverse gene disruptions, providing a broad representation of knockout-induced phenotypes while avoiding clonal bias. Optimized for suspension culture, this model facilitates functional genomics, drug screening, and mechanistic studies of the dystrophin-glycoprotein complex in a non-muscle hematopoietic context. Ready-to-use cultures enable efficient downstream applications.
K-562 cells, derived from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in blast crisis, are highly undifferentiated, Philadelphia chromosome positive, and express the BCR-ABL1 fusion protein. As a pluripotent hematopoietic progenitor, K-562 spontaneously differentiates along erythroid, granulocytic, and monocytic pathways when induced, making it a cornerstone model for hematopoiesis and leukemogenesis research. Its suspension growth habit supports large-scale culture and homogeneous experimental treatment, while the endogenous absence of dystrophin expression ensures that the knockout phenotype is assessed in a clean genetic background.
The DMD gene product dystrophin is a large cytoskeletal protein that acts as a molecular shock absorber, tethering the actin cytoskeleton to the extracellular matrix through the dystrophin-glycoprotein complex (DGC). Key DGC members include beta-dystroglycan (DAG1), the sarcoglycan complex, syntrophins (SNTA1), and dystrobrevin (DTNA), with dystrophin binding actin and beta-dystroglycan directly. Transcriptional control involves MEF2 family factors, MyoD, p53, and SOX proteins, while downstream events modulate cytoskeletal anchoring and intracellular signaling. In the K-562 background, DMD knockout permits dissection of these molecular interactions and the search for hematopoietic-specific functions distinct from the canonical sarcolemmal role.
Elimination of DMD in K-562 cells opens avenues to investigate dystrophin biology beyond muscle physiology. Although classically linked to Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy, dystrophin isoforms are present in many tissues, including hematopoietic cells. This model allows exploration of roles in hematopoietic progenitor adhesion, migration, signal transduction, and potential interplay with BCR-ABL1 signaling. It also provides a system to test pharmacological agents targeting dystrophin-related pathways, potentially revealing novel therapeutic targets for dystrophinopathies and leukemia. The polyclonal design is ideal for pooled CRISPR screens and large-scale drug sensitivity assays.
Researchers can characterize the knockout using Western blotting for dystrophin isoforms, RT-qPCR for transcript reduction, and immunofluorescence for subcellular localization. Flow cytometry enables high-throughput phenotyping of surface markers, while apoptosis and drug sensitivity assays quantify functional outcomes. RNA-seq provides a global view of transcriptomic adaptations. These suspension-adapted polyclonal cells are particularly suited for arrayed or pooled CRISPR screens and small-molecule library testing. Co-culture experiments and differentiation protocols can further dissect context-dependent dystrophin functions. For technical support or to discuss experimental customization, please contact Ascent Research.
